Tumour-targeted immunotherapy offers the unique advantage of specific tumouricidal effects with reduced immune-associated toxicity1,2. However, existing platforms suffer from low potency, inability to generate long-term immune memory and decreased activities against tumour-cell subpopulations with low targeting receptor levels3,4,5. Here we adopted a modular design approach that uses colloidal nanoparticles as substrates to create a multivalent bi-specific nanobioconjugate engager (mBiNE) to promote selective, immune-mediated eradication of cancer cells. By simultaneously targeting the human epidermal growth factor receptor 2 (HER2) expressed by cancer cells6 and pro-phagocytosis signalling mediated by calreticulin7, the mBiNE stimulated HER2-targeted phagocytosis and produced durable antitumour immune responses against HER2-expressing tumours. Interestingly, although the initial immune activation mediated by the mBiNE was receptor dependent, the subsequent antitumour immunity also generated protective effects against tumour-cell populations that lacked the HER2 receptor. Thus, the mBiNE represents a new targeted, nanomaterial-immunotherapy platform to stimulate innate and adaptive immunity and promote a universal antitumour response.
Subscribe to Journal
Get full journal access for 1 year
only $14.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012).
Bargou, R. et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321, 974–977 (2008).
Baeuerle, P. A. & Reinhardt, C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 69, 4941–4944 (2009).
Kalos, M. & June, C. H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39, 49–60 (2013).
Kershaw, M. H., Westwood, J. A. & Darcy, P. K. Gene-engineered T cells for cancer therapy. Nat. Rev. Cancer 13, 525–541 (2013).
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Chao, M. P. et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci. Transl. Med. 2, 63ra94 (2010).
Blattman, J. D. & Greenberg, P. D. Cancer immunotherapy: a treatment for the masses. Science 305, 200–205 (2004).
Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).
Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
Motzer, R. J. et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373, 1803–1813 (2015).
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
Nghiem, P. T. et al. PD-1 blockade with pembrolizumab in advanced Merkel cell carcinoma. N. Engl. J. Med. 374, 2542–2552 (2016).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
Li, A. V. et al. Generation of effector memory T cell–based mucosal and systemic immunity with pulmonary nanoparticle vaccination. Sci. Transl. Med. 5, 204ra130 (2013).
Cho, N. H. et al. A multifunctional core–shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nanotech. 6, 675–682 (2011).
Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat. Nanotech. 11, 295–303 (2016).
Li, H., Li, Y., Jiao, J. & Hu, H. M. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat. Nanotech. 6, 645–650 (2011).
Kalinski, P. et al. Dendritic cell-based therapeutic cancer vaccines: what we have and what we need. Future Oncol. 5, 379–390 (2009).
Obeid, M. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13, 54–61 (2006).
Jiang, W., Kim, B. Y. S., Rutka, J. T. & Chan, W. C. W. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotech. 3, 145–150 (2008).
Park, S. G. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160–170 (2010).
Ma, Y. et al. Targeting of antigens to B lymphocytes via CD19 as a means for tumor vaccine development. J. Immunol. 90, 5588–5599 (2013).
Feng, M. et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc. Natl Acad. Sci. USA 112, 2145–2150 (2014).
Liu, X. et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat. Med. 21, 1209–1215 (2015).
Klebanoff, C. A. et al. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc. Natl Acad. Sci. USA 102, 9571–9576 (2005).
Gardai, S. J. et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123, 321–324 (2005).
Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353–363 (2009).
Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480–489 (2011).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy Science 348, 56–61 (2015).
Qie, Y. et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci. Rep. 6, 26269 (2016).
Jiang, W., Mardyani, S., Fischer, H. & Chan, W. C. W. Design and characterization of lysine cross-linked mercapto-acid biocompatible quantum dots. Chem. Mater. 18, 872–878 (2006).
Mosser, D. M. & Zhang, X. Activation of murine macrophages. Curr. Protocol. Immunol. 83, 14.2.1–14.2.8 (2008).
Weiskopf, K. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).
The authors thank P. Anastasiadis, L. Petrucelli, H. Crawford, J. Copland, D. Radisky, T. Gonwa and D. Page and his veterinary team for reagents and helpful discussions. We also thank L. Lewis-Tuffin for her help with flow cytometer and confocal experiments, J. A. Knight, R. Feathers, H.-J. Wen and E. E. Miller for their helpful discussions, and B. Edenfield for her assistance with immunohistological experiments. Finally, we thank C. Wogan from MD Anderson's Division of Radiation Oncology for editorial contributions and AXS Studio for preparing Fig. 4d. Research reported here was supported by the James C. and Sara K. Kennedy Award from Mayo Clinic (B.Y.S.K), Jorge and Leslie Bacardi Fund for the study of Regenerative Medicine, Mayo Clinic Center for Regenerative Medicine (B.Y.S.K.), Mayo Clinic Center for Individualized Medicine Gerstner Family Award (B.Y.S.K.), Helene Houle Mayo Clinic Career Development Award in Neurologic Surgery (B.Y.S.K.), Mayo Clinic Neuroregenerative Medicine Initiative for Neuro-Oncology Research (B.Y.S.K.), China Scholarships Council (No. 201406100114, H.Y.), DeMars Family Mayo Clinic Development Fund (B.Y.S.K.) and Strawn Family Mayo Clinic Development Fund (B.Y.S.K.).
The Mayo Clinic has filed a patent application on the technology and intellectual property reported here.
About this article
Cite this article
Yuan, H., Jiang, W., von Roemeling, C. et al. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nature Nanotech 12, 763–769 (2017). https://doi.org/10.1038/nnano.2017.69
Nature Nanotechnology (2021)
Nature Nanotechnology (2021)
Chemo-physical Strategies to Advance the in Vivo Functionality of Targeted Nanomedicine: The Next Generation
Journal of the American Chemical Society (2021)
Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer
Nano Today (2021)
Antibody cooperative adsorption onto AuNPs and its exploitation to force natural killer cells to kill HIV-infected T cells
Nano Today (2021)